RxDoctor Payments Data

Roberto Martinez Quintana, MD

Pulmonary Disease · San Juan, PRNPI 1023007523

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 42.8% of the total. Reporting peaked in 2021 at $4,143 and has fallen 65.0% since, to $1,449 in 2025. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,416in general payments, 2019–2025

Across 203 payments — averaging $61.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5K
  • Sanofi$2K
  • AstraZeneca$2K
  • GSK$942
  • Boehringer Ingelheim$587
  • Amgen$308
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$5,44144%
  • Speaking & faculty fees$1,50012%
  • Food & beverage$5,47544%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,416 in reported general payments places this provider in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$27,398
Medicare patients
105
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fasenra PenBenralizumab19$108,819
FasenraBenralizumab15$86,352
Spiriva RespimatTiotropium Bromide100$53,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,478
Breo ElliptaFluticasone/Vilanterol53$26,105
Fluticasone Propionate HfaFluticasone Propionate85$25,961
Qvar RedihalerBeclomethasone Dipropionate49$14,004
SymbicortBudesonide/Formoterol Fumarate58$13,827
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,568
Albuterol Sulfate HfaAlbuterol Sulfate281$11,313
Montelukast Sodium656$9,616
Wixela InhubFluticasone Propion/Salmeterol51$8,745
Advair HfaFluticasone Propion/Salmeterol24$8,606
SynthroidLevothyroxine Sodium50$5,718
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$5,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFasenra, Symbicort, Breztri Aerosphere$1,946$111,74791 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$942$59,282110 claims
Boehringer IngelheimSpiriva Respimat$587$53,231100 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$25$14,00449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →